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Abstract
Background: Early identification of participants at risk of run-in failure (RIF) may present opportunities to improve
trial efficiency and generalizability.
Methods: We conducted a partial factorial-design, randomized, controlled trial of calcium and vitamin D to prevent
colorectal adenoma recurrence at 11 centers in the United States. At baseline, participants completed two self-
administered questionnaires (SAQs) and a questionnaire administered by staff. Participants in the full factorial
randomization (calcium, vitamin D, both, or neither) received a placebo during a 3-month single-blinded run-in;
women electing to take calcium enrolled in a two-group randomization (calcium with vitamin D, or calcium alone)
and received calcium during the run-in. Using logistic regression models, we examined baseline factors associated
with RIF in three subgroups: men (N = 1606) and women (N = 301) in the full factorial randomization and women in
the two-group randomization (N = 666).
Results: Overall, 314/2573 (12 %) participants failed run-in; 211 (67 %) took fewer than 80 % of their tablets (poor
adherence), and 103 (33 %) withdrew or were uncooperative. In multivariable models, 8- to 13-fold variation was seen
by study center in odds of RIF risk in the two largest groups. In men, RIF decreased with age (adjusted odds ratio [OR]
per 5 years 0.85 [95 % confidence interval, CI; 0.76–0.96]) and was associated with being single (OR 1.65 [95 % CI; 1.10–
2.47]), not graduating from high school (OR 2.77 [95 % CI; 1.58–4.85]), and missing SAQ data (OR 1.97 [1.40–2.76]).
Among women, RIF was associated primarily with health-related factors; RIF risk was lower with higher physical health
score (OR 0.73 [95 % CI; 0.62–0.86]) and baseline multivitamin use (OR 0.44 [95 % CI; 0.26–0.75]). Women in the 5-year
colonoscopy surveillance interval were at greater risk of RIF than those with 3-year follow-up (OR 1.91 [95 % CI; 1.08–3.
37]), and the number of prescription medicines taken was also positively correlated with RIF (p = 0.03). Perceived
toxicities during run-in were associated with 12- to 29-fold significantly increased odds of RIF.
Conclusions: There were few common baseline predictors of run-in failure in the three randomization groups. However,
heterogeneity in run-in failure associated with study center, and missing SAQ data reflect potential opportunities for
intervention to improve trial efficiency and retention.
Trial registration: ClinicalTrials.gov: NCT00153816. Registered September 2005.
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Background
The run-in period of a trial is a participatory phase
between enrollment and randomization to determine par-
ticipants’ eligibility to continue in the trial. At the end of
run-in, participants are randomized only if they meet pre-
specified criteria. A common use of the run-in period is to
identify and exclude individuals who are likely to adhere
poorly to the trial protocol. When used appropriately, this
helps to minimize dropouts after randomization [1] and
maximize trial efficiency and statistical power in the esti-
mation of efficacy, although it may impair external validity
if run-in failures (RIFs) are systematically different than
those retained in the trial. Other uses of a run-in period
are to identify and remove “placebo responders,” to iden-
tify the best effective or tolerated dose for each partici-
pant, to select participants with a good clinical response
to (or tolerance of) the active treatment [2], or to establish
baseline measurements for comparison after the interven-
tion has been applied [3]. Such uses of a run-in period
may introduce various forms of bias [4]. The run-in also
offers time before randomization for participants to
change their minds about taking part and for investigators
to verify eligibility, for example, through review of enroll-
ment blood test results and medical records.
In a trial whose placebo run-in is specifically designed
to assess adherence and select adherent participants,
participants may be largely responsible for their ineligi-
bility, e.g., due to poor pill-taking or changing their mind
about participation; in other cases they may have been
good candidates to take part if factors beyond their con-
trol had not intervened, e.g., abnormal blood test results.
Simplistically, we can think of these groups as voluntary
and involuntary RIFs, respectively. An understanding of
the characteristics associated with voluntary RIF may in-
crease efficiency in trial planning, help determine enroll-
ment targets for subgroups at risk of failing run-in, or be
used to identify participants who might be retained in
the trial using motivational strategies.
During a multicenter, randomized, placebo-controlled
trial of calcium and vitamin D in the chemoprevention
of colorectal adenoma recurrence [5], we examined the
characteristics of participants who became “voluntary
run-in failures” after an approximately 3-month single-
blinded placebo run-in period.
Methods
We conducted a randomized, double-blinded, placebo-
controlled multicenter trial of daily supplementation
with 1000 IU vitamin D3 and/or 1200 mg elemental cal-
cium as calcium carbonate, for the prevention of large
bowel adenomas [5]. Participants were recruited between
2004 and 2008 at 11 clinical centers in the continental
United States and Puerto Rico following a complete col-
onoscopy, during which at least one colorectal adenoma
was removed and none remained after the procedure.
Eligible participants aged 45–75 years were in good gen-
eral health and had no contraindications to calcium or
vitamin D, no familial colorectal cancer syndromes, and
no history of serious gastrointestinal disease. All partici-
pants provided written informed consent; the research
was approved by the Committee for the Protection of
Human Subjects at Dartmouth College and by Institu-
tional Review Boards (IRBs) at each clinical center (see
Additional file 1 for the list). The trial is reported ac-
cording to the Consolidated Standards of Reporting Tri-
als CONSORT (see Additional file 2 for the CONSORT
checklist).
Enrollment and run-in
During the informed consent process at enrollment, par-
ticipants received an explanation about the study proce-
dures, including randomized allocation to the study
agents, and were provided a copy of the signed and dated
informed consent form. Participants were mailed the SF-
36 short form health survey and food frequency question-
naires to complete at home and bring to the enrollment
interview. During a 2- to 3-hour in-person interview, they
completed a detailed intake questionnaire including ques-
tions on their beliefs about the study interventions and
the health effects of vitamin D: preference: “If you could
choose, which kind of pill would you like to receive during
the study?”; efficacy beliefs: “How likely do you think it is
that vitamin D supplements [are helpful in preventing
colon polyps]/[improve general health]/[improve pain in
bones and joints]/[improve mood or depression]/[cause
constipation]?”; and allocation belief: “If you were to place
a bet, which pill would you bet you’ll be given during the
trial?”. The latter question was poorly received by many
participants and was removed from the survey after sev-
eral months of use.
Participants were given a 7-day pill dispenser and their
first bottle of study tablets containing placebo tablets, or
calcium tablets for those in the two-group randomization,
dispensed in a single-blinded manner. Information about
the contents of the medicine bottle was shown on the
label as: “This bottle contains one of the following: cal-
cium, vitamin D, vitamin D + calcium, or placebo” or, for
the two-group randomization, “This bottle contains one
of the following: calcium, or vitamin D + calcium”, with
instructions to take one tablet twice a day with food. The
granulation and coating of the placebo tablets were com-
posed of inactive compounds such as lactose (no more
than 600 mg), cellulose, polymers, and minerals. All study
tablets were manufactured for the study and looked simi-
lar. Participants were asked to take the first tablet during
the enrollment interview; in some cases the first tablet
was taken at home, and the participant was asked to con-
firm this by postcard or telephone. Participants were also
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given a study brochure, including general instructions on
taking the tablets and specific instructions on staggered
administration if they were taking medicines that might
interact with calcium. Participants were asked to discon-
tinue any personal calcium- or vitamin D-containing sup-
plements and, for the duration of the trial, were offered a
supply of multivitamins that excluded those ingredients.
The label on the multivitamin bottle identified these as
“Multivitamin supplement” and included a complete list
of ingredients. Participants were counseled on the major
dietary sources of calcium and vitamin D and were asked
to avoid regularly consuming large amounts of such foods.
Blood was drawn at enrollment and tested for calcium,
25-hydroxyvitamin D (25-OH D), and creatinine levels.
Where possible, an appointment was scheduled for a
telephone interview in 2 to 3 months’ time. Participants
received $100 at completion of the enrollment interview.
Study coordinators and investigators were aware of the
placebo (or calcium, in the two-group randomization)
run-in, but participants were not informed about the
run-in period. During run-in, medical records were
reviewed and blood test results became available; indi-
viduals found to have disqualifying medical conditions
or abnormal blood results (including serum 25-OH D
levels <12 ng/ml) were ineligible for randomization.
Throughout the trial, perceived toxicity reports were
completed when participants reported symptoms that
they attributed to the study tablets.
Randomization
After a single-blinded run-in period of approximately
3 months (56–84 days), coordinators confirmed that the
eligibility criteria necessary for randomization had been
met, including a one-hour telephone interview to deter-
mine patient-reported eligibility criteria. They obtained
the self-reported number of tablets left in the partici-
pant’s bottle, calculated the percentage of tablets taken,
and disqualified from randomization anyone with self-
reported adherence below 80 %. RIFs were generally dis-
continued from the study before completion of the full
questionnaire. In rare cases, coordinators used their dis-
cretion, e.g., to retain a non-adherent participant who
had misunderstood the dose during run-in, or to exclude
a participant with unusual circumstances unlikely to ad-
versely affect participation.
Eligible participants who confirmed their ongoing
commitment to the study were block-randomized to
treatment in a double-blinded manner, using a web-
based random number generator, stratified by study cen-
ter, sex, and colonoscopy interval (3 or 5 years). Those
in the full factorial randomization were randomly
assigned to one of four treatment groups (calcium, vita-
min D, both, or placebo). Those in the two-group
randomization (i.e., women who were not willing to
forgo calcium supplementation) were randomized to
vitamin D or placebo and were all provided with cal-
cium. Study treatment was scheduled to continue until
the surveillance colonoscopy either 3 or 5 years after the
qualifying examination, according to recommendations
by each participant’s gastroenterologist.
Definitions: voluntary and involuntary run-in failures
RIFs were defined as individuals who enrolled and con-
sented to participate in the trial but were not random-
ized after the run-in period. We defined “voluntary”
RIFs as participants with some degree of control over
the factors that prevented their randomization, i.e., those
who declined to continue; those who took <80 % of their
study tablets; and those who could not be reached for
the telephone interview to be randomized. “Involuntary”
RIFs were defined as participants whose removal from
the trial was beyond their control, e.g., those whose
safety blood tests were abnormal; those confirmed after
enrollment as having a disqualifying medical condition;
and others who changed residence after enrollment. Had
the disqualifying medical information been available
earlier, these participants would have been ineligible for
enrollment. We focus on voluntary RIFs throughout this
paper.
Statistical methods
We reasoned that the determinants of voluntary RIF are
likely to vary in different trials, depending on the type of
intervention offered and the characteristics of partici-
pants who enroll in a particular trial. For this reason, a
priori we chose to analyze three groups of participants
separately to illustrate what might happen in parallel
“trials” with minor differences in participant characteris-
tics: (M4) men in the full factorial randomization; (F4)
women in the full factorial randomization; and (F2)
women in the two-group randomization, i.e., women
who chose to take calcium. We reasoned that the predic-
tors of RIF in a single, pooled analysis would lack exter-
nal validity, whereas common factors identified
independently in the three subgroups might generate
more plausible hypotheses that could be tested in future,
similar trials.
For each group of participants, we looked for univari-
ate associations between baseline factors and RIF using
chi-square, t test, and analysis of variance. All variables
that had a p value <0.1 in univariate analyses were added
to a ”full” logistic regression model. The final model was
obtained by removing all variables in the full model with
p > 0.05 in order to give a minimum set of variables that
together contribute significantly to the model. If signifi-
cant univariately, the reported perceived toxicity (the
only post-enrollment factor examined) was added to the
final model to allow us to assess how perceived toxicity
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influences the effect of the final model factors. For
women in the two-group randomization, multivitamin
use, calcium supplementation, and vitamin D supple-
mentation were collinear, and we chose to include only
multivitamin use in the full model.
Post hoc analyses
In general, the analysis plan and potential predictors of
RIF were selected a priori; however, during the analysis
we discovered substantial variability in RIF according to
which study center the participant had been recruited.
This was unexpected and led us to undertake several
post hoc analyses. (1) First, we recognized other vari-
ables that deserved investigation and tested those in the
models. These were: imperfect completion of the
interviewer-administered enrollment questionnaire or
the self-administered SF-36 and food frequency ques-
tionnaires; the participant’s willingness to set a date at
enrollment for the next interview; the study experience
of the enrolling staff member in prior polyp prevention
studies (dichotomous) and the total number of partici-
pants they enrolled during the entire study. For logistical
reasons, we were only able to measure this by summing
enrollments retrospectively, understanding that total ac-
crual did not reflect staff experience up to the point at
which each individual was enrolled. The variables used
in these post hoc analyses are identified as such in ta-
bles. (2) We reasoned that the observed effect of the
study center may reflect a range of factors from regional
differences among participants (e.g., education, race) to
differences in methods used by study staff; we examined
this possibility by building multivariable models without
the center variable. (3) Finally, we investigated the im-
portance of RIF rates at each center for long-term trial
efficiency by assessing the proportion failing run-in at
each center in relation to three measures of post-
randomization adherence, using scatterplots and
Kendall’s tau-b.
Odds ratios are presented with 95 % confidence inter-
vals. A single p value for each categorical variable was
estimated using a likelihood ratio test. Analyses were
done using SAS (version 9) and STATA (version 14).
Results
Of 2813 enrollees, 240 (8.5 %) were excluded from
randomization for reasons beyond their control such as
out-of-range blood test results (involuntary RIFs, Fig. 1),
leaving 2573 enrollees who were medically eligible for
randomization. A further 314/2573 (12 %) were not ran-
domized because of poor adherence or refusal to continue
in the study (voluntary RIFs, Fig. 1). The RIF proportions
among M4, F4, and F2 were 183/1606 (11 %), 49/301
(16 %), and 82/666 (12 %), respectively (Table 1). Of the
103 who declined to participate, 66 (21 % of RIFs, 2 % of
those eligible) clearly stated that they did not want to con-
tinue in our study (15 because of a perceived toxicity [PT]),
and 37 (12 % of RIFs) were uncooperative or could not be
contacted. Two-thirds (N = 211) of RIFs (8 % of those eli-
gible) were attributed to poor pill-taking adherence.
Treating the three randomization groups as though they
represent three separate study populations, the univariate
analyses identified several variables that were associated
with a higher proportion of RIF in each of the three
groups: non-white race (overall proportions in RIF and
Screened
(N=19,083) 
Voluntary run-in failures (N=314) 
Pill adherence <80% (N=211) 
Declined to participate (N=103) 
4-arm randomization men (N=183) 
4-arm randomization women (N=49) 
2-arm randomization women (N=82) 
Enrolled (N=2,813) 
4-arm randomization men (N=1741) 
4-arm randomization women (N=345) 
2-arm randomization women (N=727) 
Randomized (N=2,259) 
4-arm randomization men (N=1423) 
4-arm randomization women (N=252) 
2-arm randomization women (N=584) 
Not Enrolled (N=16,270) 
Refused (N=8,409) 
Ineligible (N=863) 
Unable to contact (N=6,802) 
Enrollment ended (N=196) 
Not Randomized (N=554) 
4-arm randomization men (N=318) 
4-arm randomization women (N=93) 
2-arm randomization (N=143) 
Involuntary run-in failures (N=240) 
Blood values out of range (N=174) 
25(OH)D < 12ng/ml (N=97) 
Calcium too high/too low (N=63) 
Creatinine too high (N=14) 
Ineligible (N=61) 
Not randomized within 84 days (N=5) 
4-arm randomization men (N=135) 
4-arm randomization women (N=44) 
2-arm randomization (N=61) 
Fig. 1 CONSORT flow diagram
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Table 1 Participant characteristics at enrollment for randomized participants and voluntary run-in failures
Full factorial randomization Two-group randomization
Men (N = 1606) Women (N = 301) Women (N = 666)
Randomized Voluntary
run-in
failure
p Randomized Voluntary
run-in
failure
p Randomized Voluntary
run-in
failure
p
N (%) N (%) N (%) N (%) N (%) N (%)
Total participants 1423 (89) 183 (11) 252 (84) 49 (16) 584 (88) 82 (12)
PERSONAL FACTORS
Age mean (SD) 58.8 (6.9) 57.5 (7.1) 0.01 56.6 (6.9) 57.5 (6.0) 0.41 56.8 (6.3) 57.3 (7.2) 0.59
Race 0.02a 0.04a 0.02a
White 1214 (90) 140 (10) 211 (85) 37 (15) 475 (90) 55 (10)
Black 100 (83) 21 (17) 31 (86) 5 (14) 53 (78) 15 (22)
Asian 35 (88) 5 (12) 1 (100) 0 (0) 15 (94) 1 (6.3)
Native American 9 (100) 0 (0) 2 (67) 1 (33) 2 (100) 0 (0)
Pacific Islander 1 (100) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Multiple races 9 (75) 3 (25) 0 (0) 1 (100) 1 (100) 0 (0)
Unknown/refused 55 (80) 14 (20) 6 (55) 5 (45) 38 (78) 11 (22)
Hispanic ethnicity <0.0001 0.06a 0.13
No 1337 (90) 154 (10) 243 (85) 44 (15) 530 (88) 70 (12)
Yes 83 (77) 25 (23) 9 (64) 5 (36) 54 (82) 12 (18)
Unknown/refused 3 (43) 4 (57) 0 0 0 0
Marital status 0.001 0.04 0.04
Married/cohabitating 1232 (90) 140 (10) 182 (87) 28 (13) 421 (89) 50 (11)
Single 191 (82) 41 (18) 70 (77) 21 (23) 162 (84) 32 (16)
Unknown/refused 0 2 (100) 0 0 1 (100) 0
Education <0.0001 0.07 0.03
Did not graduate high school 63 (71) 26 (29) 16 (70) 7 (30) 46 (78) 13 (22)
Graduated high school 196 (90) 21 (9.7) 41 (79) 11 (21) 83 (85) 15 (15)
Any college education 1164 (90) 135 (10) 195 (86) 31 (14) 455 (89) 54 (11)
HEALTH-RELATED FACTORS
Smoking status 0.40 0.06 0.46
Never 664 (89) 85 (11) 156 (88) 22 (12) 374 (89) 47 (11)
Former 629 (89) 75 (11) 71 (80) 18 (20) 150 (85) 26 (15)
Current 130 (86) 22 (14) 25 (74) 9 (26) 60 (87) 9 (13)
Unknown/refused 0 1 (100) 0 0 0 0
Alcohol use 0.96 0.32 0.10
None 341 (90) 39 (10) 116 (81) 27 (19) 233 (85) 40 (15)
≤1 drink/day 519 (90) 56 (9.7) 91 (88) 13 (12) 244 (91) 24 (9.0)
>1 drink/day 453 (90) 51 (10) 26 (79) 7 (21) 71 (86) 12 (14)
Unknown/refused 110 (75) 37 (25) 19 (90) 2 (9.5) 36 (86) 6 (14)
Activity level 0.96 0.72 0.66
Low 318 (89) 41 (11) 63 (81) 15 (19) 152 (87) 23 (13)
Moderate 424 (89) 52 (11) 86 (84) 17 (16) 202 (87) 29 (13)
High 665 (89) 86 (11) 98 (85) 17 (15) 222 (90) 26 (10)
missing 16 (80) 4 (20) 5 (100) 0 8 (67) 4 (33)
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Table 1 Participant characteristics at enrollment for randomized participants and voluntary run-in failures (Continued)
Taking a multivitamin 0.04 0.59 0.001
No 650 (87) 97 (13) 149 (83) 31 (17) 191 (82) 42 (18)
Yes 771 (90) 83 (9.7) 103 (85) 18 (15) 393 (91) 38 (8.8)
Unknown/refused 2 (40) 3 (60) 0 0 0 2 (100)
Taking calcium supplement 0.06 0.10 0.001
No 1321 (88) 174 (12) 221 (82) 47 (18) 273 (84) 53 (16)
Yes 100 (94) 6 (5.7) 30 (94) 2 (6.3) 310 (92) 27 (8.0)
Unknown/refused 2 (40) 3 (60) 1 (100) 0 1 (33) 2 (67)
Taking vitamin D supplement 0.04 0.39a 0.0001
No 1360 (88) 178 (12) 229 (83) 47 (17) 370 (84) 68 (16)
Yes 61 (97) 2 (3.2) 21 (91) 2 (8.7) 213 (95) 12 (5.3)
Unknown/refused 2 (40) 3 (60) 2 (100) 0 1 (33) 2 (67)
Number of prescription medications 0.27 0.02 0.77
0 307 (86) 50 (14) 29 (78) 8 (22) 84 (87) 13 (13)
1 360 (90) 38 (9.6) 59 (89) 7 (11) 145 (90) 16 (10)
2 273 (88) 36 (12) 51 (94) 3 (5.6) 114 (87) 17 (13)
3+ 483 (89) 59 (11) 113 (78) 31 (22) 241 (87) 36 (13)
Experienced chronic fatigue in last year 0.66 0.41a 0.11
None 1357 (89) 171 (11) 219 (83) 44 (17) 531 (89) 69 (11)
Some 51 (85) 9 (15) 23 (92) 2 (8.0) 40 (78) 11 (22)
Severe 15 (88) 2 (12) 10 (77) 3 (23) 13 (87) 2 (13)
Don’t know 0 1 (100) 0 0 0 0
Experienced muscular pain in last year 0.53 0.05 0.33
None 1228 (89) 154 (11) 210 (83) 43 (17) 488 (89) 63 (11)
Some 171 (88) 23 (12) 38 (93) 3 (7.3) 76 (85) 13 (15)
Severe 23 (82) 5 (18) 4 (57) 3 (43) 20 (80) 5 (20)
Don’t know 1 (50) 1 (50) 0 0 0 1 (100)
Experienced muscular weakness in last year 0.09 0.03a 0.31
None 1358 (89) 167 (11) 234 (83) 47 (17) 534 (88) 72 (12)
Some 54 (82) 12 (18) 16 (100) 0 38 (81) 9 (19)
Severe 11 (79) 3 (21) 2 (50) 2 (50) 11 (92) 1 (8.3)
Don’t know 0 1 (100) 0 0 1 (100) 0
Experienced bone aches or pains in last year 0.11 0.42 0.56
None 1215 (89) 151 (11) 208 (85) 37 (15) 455 (88) 63 (12)
Some 170 (89) 21 (11) 30 (77) 9 (23) 96 (89) 12 (11)
Severe 38 (79) 10 (21) 14 (88) 2 (12) 33 (83) 7 (17)
Don’t know 0 1 (100) 0 1 (100) 0 0
SF-36 mental component summary
measure, mean (SD)b
55.9 (6.0) 55.0 (7.3) 0.09 53.9 (7.5) 53.0 (10.4) 0.58 54.2 (6.9) 51.8 (8.0) 0.01
SF-36 physical component summary
measure, mean (SD)b
53.9 (6.1) 53.1 (7.5) 0.65 53.5 (6.8) 51.7 (7.5) 0.12 52.8 (6.8) 49.3 (8.9) 0.0004
ADENOMA-RELATED FACTORS
Number of baseline adenomas 0.29 0.53 0.48
0 5 (83) 1 (17) 0 0 0 1 (100)
1 916 (88) 128 (12) 190 (83) 39 (17) 453 (88) 60 (12)
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Table 1 Participant characteristics at enrollment for randomized participants and voluntary run-in failures (Continued)
2+ 502 (90) 54 (9.7) 62 (86) 10 (14) 131 (86) 21 (14)
Baseline advanced adenomas 0.73 0.98 0.12
No 1139 (89) 147 (11) 201 (84) 39 (16) 476 (87) 73 (13)
Yes 253 (88) 35 (12) 51 (84) 10 (16) 103 (92) 9 (8.0)
Unknown 31 (97) 1 (3.1) 0 0 5 (100) 0
Family history of colorectal cancer 0.14 0.40 0.73
No 1080 (88) 142 (12) 200 (84) 39 (16) 454 (88) 60 (12)
Yes 238 (92) 22 (8.5) 39 (89) 5 (11) 95 (87) 14 (13)
Unknown/refused 105 (85) 19 (15) 13 (72) 5 (28) 35 (81) 8 (19)
Colonoscopy surveillance interval 0.73 0.12 0.003
3 year 727 (88) 96 (12) 123 (87) 18 (13) 287 (92) 26 (8.3)
5 year 696 (89) 87 (11) 129 (81) 31 (19) 297 (84) 56 (16)
STUDY-RELATED FACTORS
Study center <0.0001 0.33a <0.0001
A 227 (98) 5 (2.2) 29 (85) 5 (15) 86 (97) 3 (3.4)
B 119 (97) 4 (3.3) 3 (100) 0 57 (95) 3 (5.0)
C 75 (96) 3 (3.9) 16 (100) 0 45 (96) 2 (4.3)
D 75 (90) 8 (9.6) 12 (92) 1 (7.7) 43 (96) 2 (4.4)
E 242 (88) 33 (12) 59 (86) 10 (14) 64 (93) 5 (7.3)
F 137 (87) 20 (13) 27 (87) 4 (13) 43 (66) 22 (34)
G 143 (86) 23 (14) 32 (86) 5 (14) 62 (94) 4 (6.1)
H 170 (85) 29 (15) 28 (80) 7 (20) 50 (82) 11 (18)
I 123 (83) 25 (17) 31 (74) 11 (26) 73 (84) 14 (16)
J 28 (80) 7 (20) 0 0 9 (82) 2 (18)
K 84 (76) 26 (24) 15 (71) 6 (29) 52 (79) 14 (21)
Taking prescription drug that requires
staggered administration with study
tablets
0.10 0.13 0.21
No 1310 (89) 162 (11) 204 (85) 35 (15) 472 (87) 71 (13)
Yes 113 (84) 21 (16) 48 (77) 14 (23) 112 (91) 11 (8.9)
Counseled at baseline to change diet 0.57 0.13a 0.09a
No 1381 (89) 178 (11) 250 (84) 47 (16) 578 (88) 78 (12)
Yes 42 (91) 4 (8.7) 2 (50) 2 (50) 6 (67) 3 (33)
Unknown 0 1 (100) 0 0 0 1 (100)
Refused any questions during
enrollment in-person questionnairec,d
0.01a 1.00a 0.01a
No 1419 (89) 179 (11) 251 (84) 49 (16) 583 (88) 79 (12)
Yes 4 (50) 4 (50) 1 (100) 0 1 (25) 3 (75)
Answered ”Don’t know” to any
questions during enrollment in-person
questionnairec,d
0.01 0.59a 0.05
No 1314 (89) 159 (11) 231 (84) 44 (16) 521 (89) 67 (11)
Yes 109 (82) 24 (18) 21 (81) 5 (19) 63 (81) 15 (19)
Refused any questions during
enrollment self-administered
questionnairesc
<0.0001 0.02 0.001
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randomized participants respectively, 17 % and 11 %),
lower educational attainment (overall 27 % versus 11 %),
being unmarried (overall 18 % versus 11 %), and failing to
complete one or more questions in either of the self-
administered questionnaires (overall 20 % versus 10 %)
(Table 1). In all three groups, participants at the enroll-
ment interview who confirmed a date and time for the
next appointment were less likely to fail run-in (overall
11 % versus 17 %), but this was only statistically significant
in the largest group, M4 (p < 0.001). Five additional factors
were significantly associated with RIF in univariate ana-
lyses in two of the three groups: Hispanic ethnicity, study
center, a lower SF-36 mental health score, non-use of mul-
tivitamins before the study, and answering “Don’t know”
or refusing to answer one or more questions during the
in-person enrollment interview.
Generally, participants’ preferences and beliefs about
the properties of the study tablets did not substantially
influence their probability of being randomized (Table 2).
At study entry, 63 % of participants believed that cal-
cium and vitamin D were very or somewhat likely to
prevent colorectal polyps, 34 % did not know, and 3 %
thought this unlikely. Overall, a majority of participants
believed that calcium and vitamin D were likely to im-
prove general health (86 %), improve pain in bones and
joints (63 %), or improve mood (32 %); 20 % believed
the study agents were likely to cause constipation. In
univariate analyses, beliefs about the effectiveness of cal-
cium and vitamin D and the baseline guess about alloca-
tion were not significantly associated with RIF. Although
RIF risk tended to be lower in participants who would
prefer to receive both calcium and vitamin D (overall
11 % versus 14 %), this was not statistically significant.
The multivariable models developed for the three groups
had few similarities (Tables 3, 4, 5). Study center was signifi-
cantly associated with RIF in M4 and F2, with >8-fold
variation in odds of RIF among the 11 centers in M4, and
>13-fold in F2. In M4, men who missed or refused any
question in the self-administered SF-36 or food frequency
questionnaires had more than twice the odds of failing run-
in (adjusted odds ratio [OR] 1.97; 95 % confidence interval
[CI] 1.40–2.76). Younger men were more likely to fail run-
in (adjusted OR per 5 years of age 0.85; 95 % CI 0.76–0.96),
as well as single or divorced men (adjusted OR 1.65; 95 %
CI 1.10–2.47) or men who had not graduated high school
(OR 2.77; 95 % CI 1.58–4.85). Among women in the full
factorial randomization (F4), RIF was more likely in those
reporting use of no prescription medicines or three or more
(p = 0.03). Among women in the two-group randomization
(F2), in addition to study center, RIF was inversely associ-
ated with regular use of multivitamins at baseline (adjusted
OR 0.44; 95 % CI 0.26–0.75) and SF-36 Physical Compo-
nent Summary (PCS) measure (adjusted OR 0.73; 95 % CI
0.62–0.86). Women in the 5-year colonoscopy cycle had al-
most twice the odds of run-in failure as those with 3-year
recommended follow-up (adjusted OR 1.91; 95 % CI 1.08–
3.37).
Perceived toxicities (PTs) were reported during run-in by
34 (1.8 %) participants in the full factorial randomization
and by 12 (1.8 %) women in the two-group randomization.
Table 1 Participant characteristics at enrollment for randomized participants and voluntary run-in failures (Continued)
No 1084 (91) 103 (8.7) 225 (86) 38 (14) 517 (89) 62 (11)
Yes 339 (81) 80 (19) 27 (71) 11 (29) 67 (77) 20 (23)
Scheduled next interview during
enrollmentc
0.001 0.25 0.29
No 261 (83) 52 (17) 44 (79) 12 (21) 113 (85) 20 (15)
Yes 1162 (90) 131 (10) 208 (85) 37 (15) 471 (88) 62 (12)
Number of enrollments conducted by
coordinatorc
0.42 0.31 0.76
1–10 16 (80) 4 (20) 6 (100) 0 17 (94) 1 (5.6)
11–50 170 (86) 27 (14) 28 (82) 6 (18) 86 (87) 13 (13)
51–100 364 (89) 46 (11) 77 (89) 10 (11) 132 (86) 21 (14)
>100 873 (89) 106 (11) 141 (81) 33 (19) 349 (88) 47 (12)
Coordinator worked in a prior polyp
prevention trialc
0.01 0.48 0.49
No 1034 (87) 144 (13) 211 (84) 39 (16) 413 (87) 61 (13)
Yes 389 (92) 34 (8.0) 41 (80) 10 (20) 171 (89) 21 (11)
Missing data are shown where values are not zero. p values are based on non-missing data, except for race
aFisher exact test
bp value from Kruskal-Wallis test because SF-36 scores are skewed
cNot a priori potential predictors
dExcludes questions asked as part of a skip pattern (N = 43 questions for men and 47 questions for women) and questions about beliefs in which “Don’t know”
was an allowable response
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Table 2 Participant beliefs and voluntary run-in failure
Full factorial randomization Two-group randomization
Men (N = 1606) Women (N = 301) Women (N = 666)
Randomized Voluntary
run-in
failure
p Randomized Voluntary
run-in
failure
p Randomized Voluntary
run-in
failure
p
N (%) N (%) N (%) N (%) N (%) N (%)
1423 (89) 183 (11) 252 (84) 49 (16) 584 (88) 82 (12)
BASELINE FACTORS
Preference: If you could choose, which kind of pill would you like to receive during the study?
Calcium + vitamin D 854 (90) 96 (10) 0.08 174 (87) 27 (13) 0.10a 450 (88) 62 (12) 0.37
Calcium only 67 (83) 14 (17) 13 (65) 7 (35) 34 (81) 8 (19)
Vitamin D only 63 (83) 13 (17) 8 (80) 2 (20) N/A N/A
Placebo 32 (94) 2 (5.9) 4 (100) 0 N/A N/A
Don’t know/refused 407 (88) 57 (12) 53 (80) 13 (20) 99 (89) 12 (11)
Missing 0 1 (100) 0 0 1 (100) 0
Efficacy belief: How likely do you think it is that vitamin D supplements …
Are helpful in preventing polyps 0.74 0.72 0.44
Very/somewhat likely 852 (89) 108 (11) 173 (83) 36 (17) 381 (87) 58 (13)
Don’t know 530 (89) 67 (11) 70 (86) 11 (14) 182 (89) 23 (11)
Very/somewhat unlikely 40 (85) 7 (15) 8 (80) 2 (20) 20 (95) 1 (4.8)
Refused/missing 1 (50) 1 (50) 1 (100) 0 1 (100) 0
Improve health 0.20 0.42a 0.30
Very/somewhat likely 1189 (89) 143 (11) 239 (84) 45 (16) 514 (87) 76 (13)
Don’t know 177 (85) 31 (15) 10 (77) 3 (23) 56 (90) 6 (9.7)
Very/somewhat unlikely 56 (88) 8 (13) 3 (75) 1 (25) 13 (100) 0
Refused/missing 1 (50) 1 (50) 0 0 1 (100) 0
Improve pain in bones and joints 0.59 0.63 0.18
Very/somewhat likely 902 (89) 109 (11) 176 (83) 37 (17) 347 (86) 57 (14)
Don’t know 374 (88) 51 (12) 44 (85) 8 (15) 184 (91) 18 (8.9)
Very/somewhat unlikely 145 (87) 22 (13) 32 (89) 4 (11) 52 (88) 7 (12)
Refused/missing 2 (67) 1 (33) 0 0 1 (100) 0
Improve mood 0.31 0.47 0.06
Very/somewhat likely 375 (87) 56 (13) 86 (83) 18 (17) 240 (84) 45 (16)
Don’t know 632 (90) 71 (10) 89 (87) 13 (13) 245 (91) 25 (9.3)
Very/somewhat unlikely 414 (88) 55 (12) 77 (81) 18 (19) 98 (89) 12 (11)
Refused/missing 2 (67) 1 (33) 0 0 1 (100) 0
Cause constipation 0.36 0.46 0.09
Very/somewhat likely 240 (86) 38 (14) 82 (87) 12 (13) 117 (82) 25 (18)
Don’t know 669 (89) 85 (11) 91 (83) 18 (17) 282 (90) 33 (10)
Very/somewhat unlikely 511 (90) 59 (10) 79 (81) 19 (19) 184 (88) 24 (12)
Refused/missing 3 (75) 1 (25) 0 0 1 (100) 0
Efficacy scoreb mean (SD)
compared with [randomized
participants]
2.8 (2.6) 2.5 (2.9) 0.20 3.1 (2.5) 3.4 (2.7) 0.39 3.3 (2.6) 3.6 (2.9) 0.26
Efficacy scoreb 0.16 0.94a 0.81
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Of these 46 participants, 29 (63 %) became run-in failures,
representing 12-fold increased odds of RIF in the full fac-
torial randomization groups and 29-fold in the two-group
randomization. Inclusion of PTs in the final models did not
substantially alter the estimates for the other RIF predictors
(Tables 3, 4, 5).
Study center was included in the final multivariable
model for men (Table 3) and for women in the two-
arm randomization (Table 5). When center was omit-
ted from the model of RIF in men, two factors be-
came significant: the odds of failing run-in were
higher among men who had not scheduled a time for
the next phone call before they left the enrollment
interview (OR 1.61; 95 % CI 1.11–2.33), and lower
among men enrolled by a coordinator who had
worked in a prior polyp prevention study (OR 0.64;
95 % CI 0.42–0.97) (see Additional file 3). Omission
of center from the model also led to a larger odds ra-
tio for the lowest education category (3.25; 95 % CI
1.92–5.49 from 2.77; 95 % CI 1.58–4.85). Variable se-
lection for the model for women in the two-arm
randomization was not affected by exclusion of center
(see Additional file 4).
In analyses by center, the risk of run-in was inversely
correlated with three measures of post-randomization
adherence based on pill-taking and/or endpoint ascer-
tainment, but none of these associations reached statis-
tical significance (see Additional files 5, 6, and 7).
Discussion
In this study, we analyzed data from the first 3 months
of a long-term chemoprevention trial to identify baseline
predictors of voluntary run-in failure (RIF) in three
groups of participants. In all, 12 % of participants failed
run-in, and this loss before randomization represents
considerable effort that was invested specifically to im-
prove long-term trial efficiency. Our analyses uncovered
differences in the factors associated with RIF in the three
groups, even though they experienced fundamentally the
same trial conditions. RIF risk in men was primarily as-
sociated with sociodemographic characteristics, but the
key drivers in women were health-related factors. There
were further differences in RIF predictors among women
in the full factorial and two-group randomization proto-
cols. The former group experienced a true, single-
blind, placebo run-in, whereas the latter received cal-
cium during run-in; thus, their single-blind run-in
was potentially influenced by the physiological effects
of calcium as well as any health beliefs related to
their preference for calcium supplementation. Our re-
sults illustrate the difficulties in defining a simple,
generalizable set of risk factors to identify participants
at risk of RIF. While one might expect to see differ-
ent factors affecting RIF in trials that involve different
diseases, interventions, and outcomes, here we see
different multivariable models in men and women
within the same trial.
Table 2 Participant beliefs and voluntary run-in failure (Continued)
−9 to −1 (benefit unlikely) 97 (85) 17 (15) 21 (88) 3 (13) 29 (88) 4 (12)
0 (no benefit) 149 (85) 26 (15) 16 (80) 4 (20) 49 (89) 6 (11)
1–5 (little benefit) 957 (90) 109 (10) 168 (84) 33 (16) 390 (88) 52 (12)
6–10 (some benefit) 220 (88) 31 (12) 47 (84) 9 (16) 116 (85) 20 (15)
Allocation belief: If you were to place a bet, which pill would you bet you’ll be given during the trial?
Calcium + vitamin D 236 (90) 25 (9.6) 0.96 38 (83) 8 (17) 0.89a 116 (85) 21 (15) 0.73
Calcium only 102 (89) 13 (11) 18 (82) 4 (18) 95 (88) 13 (12)
Vitamin D only 91 (90) 10 (9.9) 11 (79) 3 (21) N/A N/A
Placebo 206 (89) 25 (11) 31 (79) 8 (21) N/A N/A
Don’t know/refused 150 (91) 15 (9.1) 18 (90) 2 (10) 29 (88) 4 (12)
Missing/not askedc 638 (87) 95 (13) 136 (85) 24 (15) 344 (89) 44 (11)
POST-ENROLLMENT FACTOR
Perceived toxicity during the run-in periodd
No 1412 (89) 169 (11) <0.0001a 249 (85) 43 (15) 0.001a 581 (89) 73 (11) <0.0001a
Yes 11 (44) 14 (56) 3 (33) 6 (67) 3 (25) 9 (75)
Missing data are shown where values are not zero. p values are based on non-missing data
aFisher exact test
bEfficacy score was calculated as follows: For the first four health outcomes, extremely likely scores 2; somewhat likely scores 1; don’t know (or refused or missing)
scores 0; somewhat unlikely scores –1; extremely unlikely scores –2. For constipation, the scoring system is reversed, e.g., very likely to cause constipation scores –2. All
five scores are summed to give an overall efficacy score
cThe number of respondents is smaller because this question was removed from the questionnaire
dPerceived toxicities are defined as reports made by study coordinators on symptoms that participants attribute to the study tablets. These are identified either
during the randomization questionnaire or if participants specifically contact study coordinators to report them
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Table 3 Logistic regression models of voluntary run-in failure: full factorial study males
Unadjusted OR
(95 % CI)a
p Final model: adjusted
OR (95 % CI) C index
= 0.73
p Final model + perceived toxicity
adjusted OR (95 % CI)b C index
= 0.75
p
Total participants N = 1604 N = 1604
Age (per 5 years) 0.87 (0.78–0.97) 0.01 0.85 (0.76–0.96) 0.01 0.84 (0.75–0.95) 0.01
Race 0.01
White Reference
Black 1.82 (1.10–3.01)
Other 1.29 (0.60–2.76)
Unknown/refused 2.21 (1.20–4.07)
Hispanic ethnicity <0.0001
No Reference
Yes 2.62 (1.62–4.22)
Marital status 0.001 0.01 0.01
Single 1.89 (1.29–2.76) 1.65 (1.10–2.47) 1.73 (1.16–2.60)
Married/cohabitating Reference Reference Reference
Education <0.0001 0.001 0.004
Did not graduate high school 3.56 (2.18–5.81) 2.77 (1.58–4.85) 2.57 (1.45–4.57)
Graduated high school 0.92 (0.57–1.50) 0.93 (0.56–1.55) 0.90 (0.53–1.51)
Any college education Reference Reference Reference
Taking a multivitamin 0.04
No Reference
Yes 0.72 (0.53–0.99)
Taking calcium supplements 0.07
No Reference
Yes 0.46 (0.20–1.05)
Taking vitamin D supplements 0.06
No Reference
Yes 0.25 (0.06–1.03)
Experienced muscular weakness in last year 0.09
None Reference
Some 1.81 (0.95–3.45)
Severe 2.22 (0.61–8.03)
SF-36 mental component summary
measure (per 5 units)
0.90 (0.80–1.01) 0.08
Study center <0.0001 0.0003 0.001
A Reference Reference Reference
B 1.53 (0.40–5.79) 1.54 (0.40–5.89) 1.52 (0.40–5.84)
C 1.82 (0.42–7.78) 1.99 (0.46–8.56) 1.62 (0.36–7.27)
D 4.84 (1.54–15.25) 4.34 (1.36–13.86) 4.38 (1.37–14.02)
E 6.19 (2.38–16.13) 5.55 (2.11–14.61) 5.40 (2.04–14.27)
F 6.63 (2.43–18.05) 6.46 (2.34–17.83) 5.90 (2.12–16.42)
G 7.30 (2.71–19.63) 6.51 (2.40–17.67) 6.29 (2.30–17.18)
H 7.74 (2.94–20.41) 7.28 (2.74–19.33) 6.45 (2.41–17.29)
I 9.22 (3.45–24.69) 8.91 (3.31–24.04) 8.67 (3.20–23.52)
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In the two larger groups, study center was associated
with an 8- to 13-fold variation in odds of RIF, even after
adjustment for other factors. This substantial effect may
reflect differences in the methods used by study staff at
each center, or it may be due to residual confounding by
medical, educational, cultural, or other characteristics of
the participants. With the available data, we could not
identify differences in methods between centers. How-
ever, in post hoc analyses designed to explore the sub-
stantial heterogeneity in RIF by center, we found that
building the model without center led, among men, to
stronger associations between run-in failure and coord-
inator experience, timely scheduling of the next inter-
view, and participant education. Center may represent a
mix of factors including participant and coordinator
characteristics, participants’ uncertainty about their
commitment, and competing constraints on their time
(e.g., by employment). Center has been associated with
RIF risk in other settings [6, 7], and this association may
be worth exploring in future trials. Will a center with
more RIFs subsequently have better adherence and end-
point ascertainment because participants were more
Table 3 Logistic regression models of voluntary run-in failure: full factorial study males (Continued)
J 11.35
(3.37–38.15)
7.06 (2.01–24.76) 7.28 (2.07–26.65)
K 14.05
(5.22–37.77)
8.20 (2.96–22.70) 7.73 (2.76–21.63)
Refused any questions during in-person
enrollment questionnairec
0.004
No Reference
Yes 7.93 (1.97–31.97)
Answered ”Don’t know” to any questions
during enrollment in-person questionnairec
0.01
No Reference
Yes 1.82 (1.14–2.92)
Refused/missed any questions during
enrollment self-administered
questionnairesc
<0.0001 <0.0001 <0.0001
No Reference Reference Reference
Yes 2.48 (1.81–3.41) 1.97 (1.40–2.76) 2.09 (1.48–2.95)
Scheduled next interview phone call
during intake appointmentc
0.001
No 1.77 (1.25–2.50)
Yes Reference
Coordinator worked in a prior polyp
prevention trialc
0.01
No Reference
Yes 0.61 (0.41–0.90)
Preference: If you could choose, which kind
of pill would you like to receive during the
study?
0.09
Calcium + vitamin D Reference
Calcium only 1.86 (1.01–3.43)
Vitamin D only 1.84 (0.97–3.46)
Placebo 0.56 (0.13–2.36)
Don’t know/refused 1.25 (0.88–1.77)
Had a perceived toxicity during run-in <0.0001
No Reference
Yes 12.21 (5.08–29.33)
aIncluded were all variables that had p < 0.1 from Table 1 and baseline factors from Table 2
bFinal model plus perceived toxicity, the post-enrollment factor from Table 2
cNot a priori potential predictors
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stringently selected, or does a high RIF rate indicate a
local problem that will persist throughout the study?
Our exploratory post hoc data hinted that centers with
more RIFs had lower rates of post-randomization adher-
ence and trial completion; this might suggest local differ-
ences by center, e.g., in study methods, or in intrinsic
Table 4 Logistic regression models of run-in failure: full factorial study females
Unadjusted OR
(95 % CI)a
p Final model: adjusted OR
(95 % CI) C index = 0.62
p Final model + perceived toxicity
adjusted OR (95 % CI)b C index = 0.66
p
Total participants N = 301 N =301
Race 0.06
White Reference
Black 0.92 (0.34–2.52)
Other 2.85 (0.50–16.13)
Unknown/refused 4.75 (1.38–16.38)
Hispanic ethnicity 0.05
No Reference
Yes 3.07 (0.98–9.59)
Marital status 0.04
Married/cohabitating Reference
Single 1.95 (1.04–3.66)
Education 0.08
Did not graduate high school 2.75 (1.05–7.23)
Graduated high school 1.69 (0.79–3.63)
Any college education Reference
Smoking status 0.07
Never Reference
Former 1.80 (0.91–3.56)
Current 2.55 (1.06–6.17)
Number of prescription medications 0.03 0.03 0.03
0 Reference Reference Reference
1 0.43 (0.14–1.30) 0.43 (0.14–1.30) 0.40 (0.13–1.26)
2 0.21 (0.05–0.87) 0.21 (0.05–0.87) 0.21 (0.05–0.87)
3+ 0.99 (0.41–2.39) 0.99 (0.41–2.39) 0.97 (0.39–2.38)
Experienced muscular pain in last year 0.07
None Reference
Some 0.39 (0.11–1.31)
Severe 3.66 (0.79–16.96)
Experienced muscular weakness in last year 0.10
None/some Reference
Severe 5.32 (0.73–38.71)
Refused any questions during enrollment
self-administered questionnairesc
0.03
No Reference
Yes 2.41 (1.11–5.27)
Had a perceived toxicity during run-in 0.001
No Reference
Yes 12.26 (2.79–54.00)
aIncluded were all variables that had p < 0.1 from Table 1 and baseline factors from Table 2
bFinal model plus perceived toxicity, the post-enrollment factor from Table 2
cNot a priori potential predictors
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Table 5 Logistic regression models of run-in failure: two-group randomization females
Unadjusted OR
(95 % CI)a
p Final model: adjusted
OR (95 % CI) C index =
0.79
p Final model + perceived toxicity
adjusted OR (95 % CI)b C index =
0.81
p
Total participants N = 659 N = 659
Race 0.01
White Reference
Black 2.44 (1.29–4.62)
Other 0.48 (0.06–3.66)
Unknown/refused 2.50 (1.21–5.17)
Marital status 0.04
Married/cohabitating Reference
Single 1.66 (1.03–2.69)
Education 0.03
Did not graduate high school 2.38 (1.21–4.69)
Graduated high school 1.52 (0.82–2.83)
Any college education Reference
Taking a multivitaminc 0.001 0.002 0.004
No Reference Reference Reference
Yes 0.44 (0.27–0.71) 0.44 (0.26–0.75) 0.45 (0.26–0.77)
Taking calcium supplementsc 0.001
No Reference
Yes 0.45 (0.28–0.73)
Taking vitamin D supplementsc
No Reference 0.0003
Yes 0.31 (0.16–0.58)
SF-36 mental component summary
measure (per 5 units)
0.81 (0.70–0.94) 0.01
SF-36 physical component summary
measure (per 5 units)
0.75 (0.65–0.86) <0.0001 0.73 (0.62–0.86) 0.0002 0.70 (0.58–0.83) <0.0001
Study center <0.0001 <0.0001 <0.0001
A Reference Reference Reference
B 1.51 (0.29–7.74) 0.86 (0.14–5.42) 1.00 (0.15–6.56)
C 1.27 (0.21–7.90) 1.39 (0.22–8.82) 1.68 (0.25–11.13)
D 1.33 (0.22–8.28) 1.07 (0.17–6.85) 1.23 (0.19–8.17)
E 2.24 (0.52–9.72) 1.84 (0.42–8.18) 1.88 (0.40–8.85)
F 14.67 (4.16–51.74) 13.17 (3.65–47.58) 14.37 (3.76–55.00)
G 1.85 (0.40–8.56) 2.02 (0.43–9.52) 1.97 (0.38–10.30)
H 6.31 (1.68–23.69) 4.90 (1.28–18.80) 5.32 (1.31–21.53)
I 5.50 (1.52–19.88) 5.58 (1.51–20.68) 6.18 (1.58–24.18)
J 6.37 (0.94–43.30) 5.36 (0.73–39.45) 6.63 (0.85–51.46)
K 7.72 (2.12–28.14) 4.12 (1.06–15.97) 3.12 (0.75–13.02)
Colonoscopy surveillance interval 0.004 0.03 0.02
3 years Reference Reference Reference
5 years 2.08 (1.27–3.41) 1.91 (1.08–3.37) 2.06 (1.13–3.74)
Refused any questions during
enrollment intake questionnaired
0.01
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differences among the participants who enrolled in each
region.
Among men, those who were younger, single, and had
not graduated high school had the greatest risk of failing
run-in. One possible explanation is that those who were
working had less time to commit to the study than re-
tired participants, but we did not collect employment
data. In addition, men had twice the risk of RIF if they
overlooked or refused to answer one or more questions
in two self-administered questionnaires (SAQs). This
finding might be explained by an association between
perfect completion of the SAQ and an individual’s moti-
vations underlying trial participation. However, an alter-
native explanation is differences in quality checking by
study staff; those who more effectively identified missing
SAQ questions and had participants correct them may
have also been better at motivating enrollees during en-
rollment and run-in. With our data, we could not
distinguish these two possibilities. The first suggests that
a SAQ could be developed to help identify individuals at
risk of run-in failure and target them for intervention.
The second could be addressed via improvements in
staff training and motivational protocols.
In women, health-related factors tended to be associ-
ated with RIF. In the full factorial randomization, RIF
was most frequent among women taking no prescription
medications at baseline. Among women in the two-
group randomization, RIF was less common among
women who took vitamin supplements at baseline, had
better SF-36 physical health scores, and a 3-year (rather
than a 5-year) trial participation, which represents not
only a shorter commitment to trial participation, but
also higher risk adenomas that require more intensive
follow-up. We found no convincing evidence that the
successful negotiation of run-in was associated with par-
ticipants’ expectations of health benefits from the agents,
Table 5 Logistic regression models of run-in failure: two-group randomization females (Continued)
No Reference
Yes 22.14
(2.28–215.43)
Answered ”Don’t know” to any
questions during enrollment intake
questionnaired
0.05
No Reference
Yes 1.85 (1.00–3.43)
Refused any questions during
enrollment self-administered
questionnairesd
0.002
No Reference
Yes 2.49 (1.42–4.38)
Counseled at baseline to change dietd 0.07
No Reference
Yes 3.71 (0.91–15.12)
Improve mood 0.06
Very/somewhat likely Reference
Don’t know 0.54 (0.32–0.92)
Very/somewhat unlikely 0.65 (0.33–1.29)
Cause constipation 0.10
Very/somewhat likely Reference
Don’t know 0.55 (0.31–0.96)
Very/somewhat unlikely 0.61 (0.33–1.12)
Had a perceived toxicity during the
run-in period
<0.0001
No Reference
Yes 29.02 (6.83–123.33)
aIncluded were all variables that had p < 0.1 from Table 1 and baseline factors from Table 2
bFinal model plus perceived toxicity, the post-enrollment factor from Table 2
cBaseline multivitamin, calcium, and vitamin D supplement use were collinear variables; the first was included in the model
dNot a priori potential predictors
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which tablets they would prefer if given the choice, or
which agents they guessed they would be given for the
study. Other studies have found that trial participation is
associated with altruistic factors [8–11], so it is possible
that individuals with stronger feelings about the study
agents were less likely to enroll in the first place.
Predictors of RIF have varied in previous trials. RIF
was associated with lower Karnofsky performance score
and lower education level in a head and neck cancer
chemoprevention trial [12], and with younger age, not
working, and smoking, in a trial of pregnant women to
prevent adverse neonatal outcomes [7]. Interestingly, in
the latter study, the proportions of RIFs ranged from
20–40 % in five clinics but was lowest in one clinic
where participants were told they would receive sugar
pills during run-in. Another trial of motivational inter-
ventions to reduce blood pressure found no significant
characteristics of RIFs, but the sample was small [1].
In our trial and others, the purpose of the adherence
run-in is to help researchers identify and randomize the
participants most likely to follow trial protocol. Its poten-
tial advantages include the retention of good long-term
adherers [13], improved efficiency [14], improved internal
validity in the estimation of efficacy, and greater statistical
precision [15]. There is certainly evidence that removing
poor adherers can change a study’s effect estimates. For
example, in a trial of lovastatin to reduce cholesterol
levels, Davis et al. found that participants who would have
failed run-in had an adherence criterion been applied, ex-
perienced 17.8 % smaller cholesterol reductions than more
adherent participants [6]. By retaining these individuals in
the trial, the proportion of less educated participants was
increased (improving generalizability), but the overall
measure of lovastatin’s effectiveness was 5.2 % lower than
it would otherwise have been. Pablos-Mendez discussed
two comparable trials of aspirin to prevent myocardial in-
farction [2]. The first trial, in American physicians, in-
cluded a run-in and reported 90 % adherence over 5 years
and a significant risk reduction of 44 % [16]. The other
trial, in British physicians, did not include a run-in, and
reported adherence of 70 % over 6 years and a non-
significant risk reduction of 3 % [17]. These findings sup-
port the use of run-in to improve adherence, provided that
the goal is to estimate efficacy rather than effectiveness.
One concern about the adherence run-in is that indi-
viduals who adhere poorly to treatment are very differ-
ent than those who adhere well, with respect to health
and other characteristics; poor adherers have worse
health outcomes during clinical trials independent of as-
signment to the active or placebo group [18–23], and
their exclusion may therefore reduce generalizability.
Further, improvements in efficiency offered by the run-
in may be attenuated if the exclusion criteria misclassify
individuals who would have gone on to complete the
trial successfully [14]. Although early trial adherence and
longer term adherence tend to be highly correlated [7],
one study showed that this was true for less educated
participants but not for more educated ones [6]. The im-
plication is that exclusion of better educated participants
who adhere poorly during run-in may be relatively ineffi-
cient because their longer term adherence is less accur-
ately predicted. However, although the factors associated
with adherence in different settings have been studied
extensively [24, 25], RIF is not simply an adherence
issue; it also gives participants an opportunity to recon-
sider their enrollment (“buyer’s remorse”). In one study,
when patients were interviewed within a month of en-
rollment in a variety of clinical trials, 16 (12 %) had
already considered dropping out, and 4 of those contin-
ued because of a sense of obligation, despite a preference
to withdraw [26]. In our study, 21 % of RIFs (4 % of
enrollees medically eligible for randomization) clearly
stated that they did not want to continue participating,
and a further 12 % were uncooperative or could not be
contacted. But among the two-thirds of RIFs we attrib-
uted to poor adherence, ambivalence towards trial par-
ticipation may have been the underlying cause of that
poor adherence in some cases. It is also possible that the
$100 incentive payment was the primary motivation for
enrollment; this may account for some early dropouts.
Future studies of run-in might collect more granular
data to distinguish poor adherence from disinclination
to continue in the trial. Potential strategies to address
both problems may include increased communication
with participants during run-in to elicit questions and
concerns, motivate participants in their pill-taking rou-
tine, and develop a rapport that encourages individuals
to stay in the trial. One option might be a two-stage
run-in. For example, in our trial, participants could have
been telephoned one week after enrollment to assess
early adherence, identify cases of “buyer’s remorse,” and
provide explanations and motivational counseling where
appropriate. After 3 months, persistent non-adherers
could be excluded from randomization as usual, and
randomization could be stratified according to whether
motivational counseling was initiated, to assess the im-
pact of the strategy by subgroup. This approach could
be extended to study the ideal frequency of participant
contact or counseling needed to retain promising partic-
ipants but not reluctant enrollees with poor long-term
prospects of adherence.
Forty-six participants (2 % of enrollees and 15 % of RIFs)
contacted their coordinator to report perceived toxicities
(PTs) during run-in, and almost two-thirds of those be-
came RIFs. In the full factorial randomization, participants
received placebo during run-in and PTs were associated
with a 12-fold increased odds of RIF. In the two-group
randomization, women receiving calcium and reporting a
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PT experienced a 29-fold increase in odds of RIF. How-
ever, the risk of PT was similar in those given placebo or
calcium during run-in. When a participant develops any
new symptom by chance during run-in, they may attribute
it to the study intervention; alternatively, the PT may be a
nocebo phenomenon arising from expectations of an ad-
verse effect upon starting a new treatment. Up to a quar-
ter of patients in the placebo group in previous trials have
reported symptoms after randomization, with a wide
range of frequency across trials [27–29]. Some trials delib-
erately exclude participants who show a placebo response
(or a coincident improvement in health) during run-in,
but they may be criticized for poorer generalizability [4].
What we observed was an increased tendency for partici-
pants with a nocebo response (or coincidental develop-
ment of symptoms) to fail run-in. Both types of exclusion
involve a change in health while taking placebo: the first,
determined by the investigator, excludes those with benefi-
cial changes in health while taking placebo, while the sec-
ond type, determined by the participant, excludes those
with adverse changes in health. Both are likely to affect
generalizability. Although PTs were very strongly associ-
ated with RIF, it is unclear how to address this, because if
the blind must be maintained, participants cannot be told
that they were taking placebo during run-in.
This study was limited by differences in sample size in
the three subgroups, which will have affected the power to
consistently detect factors with common specific effect
sizes and meant that our multivariable modeling did not
directly compare RIF rates in men and women. In
addition, we chose to only consider main effects in our
analyses and did not model any interactions between po-
tential predictor variables. A further limitation was our
use of self-reported adherence via tablet counts, which, al-
though superior to some methods, is still subject to mis-
classification [30]. Our study was a relatively long-term
(3- to 5-year) trial using agents (calcium and vitamin D)
that are generally thought to have few, if any, adverse side
effects. As a chemoprevention trial, it recruited individuals
with a specific interest in preventive health strategies, and
our study was also limited to adults aged 45–75 in good
general health. The study may therefore have limited
generalizability to other types of trials, although this
would be more of a concern if we had found a consistent
set of RIF predictors in the three subgroups and were pro-
posing to extend our findings to diverse trial settings.
Conclusions
The lack of a clear, single set of predictors of run-in fail-
ures among our three subgroups suggests that the search
for general predictors of run-in failure in trials will not be
straightforward. However, substantially different risks as-
sociated with study center and missing self-administered
questionnaire data reflect opportunities for further study
with the goal of identifying interventions that might im-
prove trial efficiency and retention. Perceived toxicities
during a placebo run-in represent the strongest risk factor
for run-in failure, but perhaps are the most difficult to ad-
dress in a blinded study. The loss of 12 % of participants
due to voluntary factors represents considerable expense
as well as loss of generalizability, and the search for a bal-
ance between optimal efficiency and generalizability via
the adherence run-in deserves further attention.
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